**Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia and COVID-19**

**Professional Legal Representative - Brief Information Summary:**

**What is it?**

REMAP-CAP is a clinical trial designed to understand the best treatment options for COVID-19. When a patient with COVID-19 becomes ill there are several types of drugs that may help them recover. REMAP-CAP has been designed to test different types of drugs and the various combinations of these treatments.

**What are the treatments?**

We are testing various treatments both on the **in ICU.**

The treatments in **ICU** include **1) combination of antibiotics, 2) duration of macrolide treatment, 3) vitamin C therapy, 4) simvastatin therapy, 5) anticoagulation therapy** and **6) ACE2/RAS therapies 7) Cysteamine therapy, therapy 8) Monoclonal Antibody Therapy (Ronapreve) and 9) Immunoglobulin therapy (Convalescent Plasma).** Patients in this study may be treated with any combination of these drugs because it is important to understand what is the best combination of treatments.

Many of the treatment options listed above also include a ‘no treatment’ option and so the patient may not receive any of these treatments if they choose to participate.

**Will all treatments be offered to the patient?**

Your hospital can select which treatments they would like to participate in. The patient will be randomised to all treatment options available at site. REMAP-CAP is a randomised trial so that balanced groups are compared, and this allows us to understand which way is best to treat patients. Additionally, this study uses adaptive randomisation. This means that the chances of being assigned to any of the treatment options may change based on the study results, in favour of the most promising treatment.

**Current findings**

Due to our ‘adaptive’ model we can evaluate treatment options quickly and have so far discovered that the use of hydrocortisone reduces the need for organ support in patients with COVID-19. We also demonstarted that the immune modulators, tocilizumab and sarilumab, both improve outcomes in critically ill patient with COVID-19. These interventions are now Standard of Care in ICUs in the UK.

As this is an emergency situation, treatment should be started as quickly as possible and may need to be started before we can speak to the patient or family members to seek formal consent. As soon as practical the patient or family & friends should be updated. This brief summary can be used to provide some simple information. Full detailed information sheets are also available. Please document all conversations with patients or next of kin in the patient’s notes. If patients don’t want to take part that is their choice and should be respected and this will not affect the standard of care that they receive. Please document their wishes in the notes so that they don’t get included in an emergency situation.

 